USP9X inhibition by the small molecule WP1130 induces BCR-ABL ubiquitination and trafficking, leading to apoptosis in both imatinib-sensitive and -resistant CML cells. Here, USP9X is linked to chronic myelogenous leukemia, BCR-ABL1 positive.